Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

API gains boost Ipca’s sales

Executive Summary

A 27% rise in turnover from active pharmaceutical ingredients (APIs) contributed to Ipca Laboratories increasing its group turnover by just over a fifth to Rs8.68 billion (US$121 million) in its financial first quarter ended 30 June 2018. Exports of APIs climbed by 17% to Rs1.58 billion, while the Indian company’s domestic sales of bulk drugs shot up by two-thirds to Rs600 million (see Figure 1).

You may also be interested in...



Ipca Adds To API Business By Acquiring Ramdev

India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.

Clinical Trial Diversity Would Benefit From Regulatory, Financial Incentives, Experts Say

Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.

Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?

CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel